EQT Withdraws Takeover Bid for Oxford Biomedica
Private equity group EQT has decided not to proceed with its takeover offer for Oxford Biomedica. The move caused the company's shares to drop nearly 10%.
The private equity group EQT AB (publ)[Symbol:{ \"assets\":{ \"symbol\":\"EQT.ST\" } }] has announced its decision to abandon a potential takeover bid for Oxford Biomedica plc[Symbol:{ \"assets\":{ \"symbol\":\"OXB.L\" } }]. The news, released on Wednesday, triggered a significant sell-off in the shares of the United Kingdom[Country:{ \"assets\":{ \"country\":\"GB\" } }]-based cell and gene therapy manufacturer, with its stock price dropping by nearly 10% during early trading.
The withdrawal marks a sudden conclusion to what many expected to be a major acquisition in the biotechnology sector. Oxford Biomedica plc is recognized globally for its specialized viral vector development and manufacturing capabilities, which are essential for the production of advanced gene therapies. The company has been a key partner for various pharmaceutical firms in the development of life-saving treatments.
Following the announcement, market analysts pointed to the volatility inherent in the biotech sector, especially concerning large-scale private equity deals. While the specific reasons for EQT AB (publ) backing out were not disclosed, the impact on Oxford Biomedica plc's market valuation was immediate. The company remains a critical infrastructure provider for the pharmaceutical industry, despite the lack of a current takeover offer.
